URANIUM ROYALTY CORP (UROY) Fundamental Analysis & Valuation

NASDAQ:UROY • CA91702V1013

Current stock price

3.58 USD
-0.06 (-1.65%)
At close:
3.59 USD
+0.01 (+0.28%)
After Hours:

This UROY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. UROY Profitability Analysis

1.1 Basic Checks

  • UROY had positive earnings in the past year.
  • UROY had a positive operating cash flow in the past year.
  • UROY had negative earnings in 4 of the past 5 years.
  • UROY had a negative operating cash flow in each of the past 5 years.
UROY Yearly Net Income VS EBIT VS OCF VS FCFUROY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • UROY has a Return On Assets of 1.15%. This is in the lower half of the industry: UROY underperforms 60.29% of its industry peers.
  • UROY's Return On Equity of 1.15% is on the low side compared to the rest of the industry. UROY is outperformed by 64.11% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 0.37%, UROY is doing worse than 71.29% of the companies in the same industry.
Industry RankSector Rank
ROA 1.15%
ROE 1.15%
ROIC 0.37%
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
UROY Yearly ROA, ROE, ROICUROY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

  • UROY has a Profit Margin (8.03%) which is in line with its industry peers.
  • The Operating Margin of UROY (3.28%) is worse than 67.46% of its industry peers.
  • UROY has a worse Gross Margin (19.67%) than 65.55% of its industry peers.
Industry RankSector Rank
OM 3.28%
PM (TTM) 8.03%
GM 19.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UROY Yearly Profit, Operating, Gross MarginsUROY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

8

2. UROY Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), UROY is destroying value.
  • UROY has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for UROY has been increased compared to 5 years ago.
  • Compared to 1 year ago, UROY has a worse debt to assets ratio.
UROY Yearly Shares OutstandingUROY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
UROY Yearly Total Debt VS Total AssetsUROY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • UROY has an Altman-Z score of 311.91. This indicates that UROY is financially healthy and has little risk of bankruptcy at the moment.
  • UROY's Altman-Z score of 311.91 is amongst the best of the industry. UROY outperforms 100.00% of its industry peers.
  • The Debt to FCF ratio of UROY is 0.00, which is an excellent value as it means it would take UROY, only 0.00 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.00, UROY belongs to the top of the industry, outperforming 91.87% of the companies in the same industry.
  • UROY has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • UROY's Debt to Equity ratio of 0.00 is amongst the best of the industry. UROY outperforms 83.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 311.91
ROIC/WACC0.05
WACC7.99%
UROY Yearly LT Debt VS Equity VS FCFUROY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 325.28 indicates that UROY has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 325.28, UROY belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • UROY has a Quick Ratio of 139.82. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
  • UROY has a Quick ratio of 139.82. This is amongst the best in the industry. UROY outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 325.28
Quick Ratio 139.82
UROY Yearly Current Assets VS Current LiabilitesUROY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

3

3. UROY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 487.04% over the past year.
  • The Revenue has grown by 136.01% in the past year. This is a very strong growth!
EPS 1Y (TTM)487.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)136.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%416400%

3.2 Future

  • Based on estimates for the next years, UROY will show a very strong growth in Earnings Per Share. The EPS will grow by 122.46% on average per year.
  • Based on estimates for the next years, UROY will show a very negative growth in Revenue. The Revenue will decrease by -37.84% on average per year.
EPS Next Y5105.11%
EPS Next 2Y87.12%
EPS Next 3Y122.46%
EPS Next 5YN/A
Revenue Next Year251.54%
Revenue Next 2Y-79.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A

3.3 Evolution

UROY Yearly Revenue VS EstimatesUROY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
UROY Yearly EPS VS EstimatesUROY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05 0.1 0.15

3

4. UROY Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 179.00, UROY can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of UROY indicates a slightly more expensive valuation: UROY is more expensive than 68.90% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.86. UROY is valued rather expensively when compared to this.
  • The Price/Forward Earnings ratio is 979.86, which means the current valuation is very expensive for UROY.
  • Based on the Price/Forward Earnings ratio, UROY is valued a bit more expensive than the industry average as 65.55% of the companies are valued more cheaply.
  • UROY is valuated expensively when we compare the Price/Forward Earnings ratio to 37.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 179
Fwd PE 979.86
UROY Price Earnings VS Forward Price EarningsUROY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 200 400 600 800

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, UROY is valued a bit more expensive than 72.73% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, UROY is valued a bit cheaper than the industry average as 60.77% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 18.66
EV/EBITDA 289.13
UROY Per share dataUROY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

  • UROY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as UROY's earnings are expected to grow with 122.46% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y87.12%
EPS Next 3Y122.46%

0

5. UROY Dividend Analysis

5.1 Amount

  • No dividends for UROY!.
Industry RankSector Rank
Dividend Yield 0%

UROY Fundamentals: All Metrics, Ratios and Statistics

URANIUM ROYALTY CORP

NASDAQ:UROY (4/10/2026, 8:00:01 PM)

After market: 3.59 +0.01 (+0.28%)

3.58

-0.06 (-1.65%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)03-10
Earnings (Next)07-14
Inst Owners31.03%
Inst Owner Change0.01%
Ins Owners1.99%
Ins Owner ChangeN/A
Market Cap524.40M
Revenue(TTM)54.60M
Net Income(TTM)4.38M
Analysts75
Price Target4.24 (18.44%)
Short Float %5.6%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)248.52%
Min EPS beat(2)199.01%
Max EPS beat(2)298.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.3%
PT rev (3m)6.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)899.82%
EPS NY rev (3m)899.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)0.95%
Valuation
Industry RankSector Rank
PE 179
Fwd PE 979.86
P/S 13.27
P/FCF 18.66
P/OCF 18.17
P/B 1.9
P/tB 1.9
EV/EBITDA 289.13
EPS(TTM)0.02
EY0.56%
EPS(NY)0
Fwd EY0.1%
FCF(TTM)0.19
FCFY5.36%
OCF(TTM)0.2
OCFY5.5%
SpS0.27
BVpS1.88
TBVpS1.88
PEG (NY)0.04
PEG (5Y)N/A
Graham Number0.92
Profitability
Industry RankSector Rank
ROA 1.15%
ROE 1.15%
ROCE 0.47%
ROIC 0.37%
ROICexc 0.58%
ROICexgc 0.58%
OM 3.28%
PM (TTM) 8.03%
GM 19.67%
FCFM 71.16%
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0.06
Cap/Depr 561.29%
Cap/Sales 1.91%
Interest Coverage 250
Cash Conversion 2018.06%
Profit Quality 886.04%
Current Ratio 325.28
Quick Ratio 139.82
Altman-Z 311.91
F-Score7
WACC7.99%
ROIC/WACC0.05
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)487.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y5105.11%
EPS Next 2Y87.12%
EPS Next 3Y122.46%
EPS Next 5YN/A
Revenue 1Y (TTM)136.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%416400%
Revenue Next Year251.54%
Revenue Next 2Y-79.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A
EBIT growth 1Y314.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1279.09%
EBIT Next 3Y3.56%
EBIT Next 5YN/A
FCF growth 1Y141.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y142.53%
OCF growth 3YN/A
OCF growth 5YN/A

URANIUM ROYALTY CORP / UROY Fundamental Analysis FAQ

What is the fundamental rating for UROY stock?

ChartMill assigns a fundamental rating of 4 / 10 to UROY.


Can you provide the valuation status for URANIUM ROYALTY CORP?

ChartMill assigns a valuation rating of 3 / 10 to URANIUM ROYALTY CORP (UROY). This can be considered as Overvalued.


Can you provide the profitability details for URANIUM ROYALTY CORP?

URANIUM ROYALTY CORP (UROY) has a profitability rating of 1 / 10.


How financially healthy is URANIUM ROYALTY CORP?

The financial health rating of URANIUM ROYALTY CORP (UROY) is 8 / 10.


What is the earnings growth outlook for URANIUM ROYALTY CORP?

The Earnings per Share (EPS) of URANIUM ROYALTY CORP (UROY) is expected to grow by 5105.11% in the next year.